

CLAIMS

1. A method of treating hyperlipidemia in a patient, said method comprising administering a therapeutically effective amount of a somatostatin type-5 receptor agonist to said patient.

2. A method of claim 1, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

3. A method of treating hyperlipidemia in a patient, said method comprising administering a therapeutically effective amount of a somatostatin type-5 receptor selective agonist to said patient.

4. A method of claim 3, wherein said somatostatin type-5 receptor selective agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

5. A method of claim 1, said method comprising administering a therapeutically effective amount of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, where a disulfide bond exists between the free thiols of the two Cys residues, or H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>.

6. A method of lowering the amount of triacylglycerols, glycerol, or cholesterol in the blood of a patient, said method comprising administering a therapeutically effective amount of a somatostatin type-5 receptor agonist to said patient.

7. A method of lowering the amount of triacylglycerols, glycerol, or cholesterol in the blood

of a patient, said method comprising administering a therapeutically effective amount of a somatostatin type-5 receptor selective agonist to said patient.

8. A method of claim 6, wherein said method  
5 comprises lowering the amount of triacylglycerols in said patient.

9. A method of claim 8, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

10. A method of claim 7, wherein said method  
10 comprises lowering the amount of triacylglycerols in said patient.

11. A method of claim 10, wherein said somatostatin type-5 receptor selective agonist has a  $K_i$   
15 for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

12. A method of claim 8, said method comprising administering a therapeutically effective amount of H-  
20 Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, where a disulfide bond exists between the free thiols of the two Cys residues, or H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>.

13. A method of claim 6, wherein said method  
25 comprises lowering the amount of glycerol in said patient.

14. A method of claim 13, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.

15. A method of claim 7, wherein said method comprises lowering the amount of glycerol in said patient.

16. A method of claim 15, wherein said  
5 somatostatin type-5 receptor selective agonist has a  $K_i$  for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.

17. A method of claim 13, said method comprising  
10 administering a therapeutically effective amount of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, where a disulfide bond exists between the free thiols of the two Cys residues, or H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>.

18. A method of claim 6, wherein said method  
15 comprises lowering the amount of cholesterol in said patient.

19. A method of claim 18, wherein said somatostatin type-5 receptor agonist has a  $K_i$  of less than 2 nM for the somatostatin type-5 receptor.


20. A method of claim 7, wherein said method  
20 comprises lowering the amount of total cholesterol or LDL cholesterol in said patient.

21. A method of claim 20, wherein said somatostatin type-5 receptor selective agonist has a  $K_i$   
25 for the type-5 somatostatin receptor that is at least 10 times less than its  $K_i$  for the somatostatin type-2 receptor.


22. A method of claim 18, said method comprising administering a therapeutically effective amount of H-  
30 Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub>, where a disulfide

bond exists between the free thiols of the two Cys residues, or H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH<sub>2</sub>.

23. A method according to claim 1 wherein the somatostatin type-5 receptor agonist is
- 5 H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,




or




10

24. A method according to claim 8 wherein the somatostatin type-5 receptor agonist is
- H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> ,  
 15 H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,




or




20

25. A method according to claim 13 wherein the somatostatin type-5 receptor agonist is
- H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> ,  
 H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,

H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,



or




5 .

26. A method according to claim 18 wherein the somatostatin type-5 receptor agonist is


H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH<sub>2</sub> ,

10 H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,

H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH<sub>2</sub> ,



or



15 .

27. A pharmaceutical composition comprising a therapeutically effective amount of a somatostatin type-5 receptor, optionally selective, agonist.

20 28. A pharmaceutical composition as claimed in claim 27, said agonist having the features identified in any one of claims 2, 4, 5 and 23 to 26.

29. Use of a somatostatin type-5 receptor, optionally selective, agonist in the formulation of a  
25 pharmaceutical composition for use in treating hyperlipidemia, or reducing the amount of

tracylglycerols, glycerol, or cholesterol in a human or mammalian animal.

30. Use of a somatostatin agonist according to claim 29, wherein said somatostatin agonist has the  
5 relevant features identified in any one of claims 2, 4, 5 and 23 to 26.

31. A pharmaceutical composition substantially as hereinbefore described with reference to the Examples.